Cargando…

Clinical outcome of patients with pancreatic metastases from renal cell cancer

BACKGROUND: Renal cell cancer (RCC) is one of the most frequent primary sites for metastatic pancreatic tumors although metastatic tumors are rare among pancreatic malignant tumors. The purpose of this study is to disclose the characterization and treatment outcomes of pancreatic metastases from RCC...

Descripción completa

Detalles Bibliográficos
Autores principales: Yuasa, Takeshi, Inoshita, Naoko, Saiura, Akio, Yamamoto, Shinya, Urakami, Shinji, Masuda, Hitoshi, Fujii, Yasuhisa, Fukui, Iwao, Ishikawa, Yuichi, Yonese, Junji
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2015
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4332740/
https://www.ncbi.nlm.nih.gov/pubmed/25872621
http://dx.doi.org/10.1186/s12885-015-1050-2
_version_ 1782357951983386624
author Yuasa, Takeshi
Inoshita, Naoko
Saiura, Akio
Yamamoto, Shinya
Urakami, Shinji
Masuda, Hitoshi
Fujii, Yasuhisa
Fukui, Iwao
Ishikawa, Yuichi
Yonese, Junji
author_facet Yuasa, Takeshi
Inoshita, Naoko
Saiura, Akio
Yamamoto, Shinya
Urakami, Shinji
Masuda, Hitoshi
Fujii, Yasuhisa
Fukui, Iwao
Ishikawa, Yuichi
Yonese, Junji
author_sort Yuasa, Takeshi
collection PubMed
description BACKGROUND: Renal cell cancer (RCC) is one of the most frequent primary sites for metastatic pancreatic tumors although metastatic tumors are rare among pancreatic malignant tumors. The purpose of this study is to disclose the characterization and treatment outcomes of pancreatic metastases from RCC. METHODS: Of 262 patients with metastatic RCC treated at our hospital between 1999 and 2013, the data of 20 (7.6%) who simultaneously developed or subsequently acquired pancreatic metastases were retrospectively reviewed and statistically analyzed. RESULTS: The median follow-up period from RCC diagnosis and pancreatic metastases was 13.4 years (inter-quartile range: IQR, 7.8–15.5 years) and 3.8 years (IQR, 2.1–5.5 years), respectively. Median duration from diagnosis of RCC to pancreatic metastasis was 7.8 years (IQR, 4.2–12.7 years). During this observation period, the estimated median overall survival (OS) time from the diagnosis of RCC to death or from pancreatic metastasis to death was not reached. The probability of patients surviving after pancreatic metastasis at 1, 3, and 5 years was 100, 87.7, and 78.9%, respectively. The estimated OS period from the diagnosis of metastases to death of the patients with pancreatic metastasis was significantly longer than that of the patients with non-pancreatic metastasis (median OS 2.7 years) (P < 0.0001). Surgical management for pancreatic metastasis was performed in 15 patients (75%). When the median follow-up period for these surgeries was 3.5 years (IQR, 1.9–5.2 years), the estimated median recurrence-free survival was 1.8 years. For the patients with multiple metastatic sites, molecularly targeted therapies were given to six (30%) patients. When the median follow-up period was 4.1 years (IQR, 3.0–4.4 years), no disease progression was observed. CONCLUSIONS: The pancreas is frequently the only metastatic site and metastasis typically occurs a long time after nephrectomy. The OS period of these patients is long and both surgical and medical treatment resulted in good outcomes.
format Online
Article
Text
id pubmed-4332740
institution National Center for Biotechnology Information
language English
publishDate 2015
publisher BioMed Central
record_format MEDLINE/PubMed
spelling pubmed-43327402015-02-20 Clinical outcome of patients with pancreatic metastases from renal cell cancer Yuasa, Takeshi Inoshita, Naoko Saiura, Akio Yamamoto, Shinya Urakami, Shinji Masuda, Hitoshi Fujii, Yasuhisa Fukui, Iwao Ishikawa, Yuichi Yonese, Junji BMC Cancer Research Article BACKGROUND: Renal cell cancer (RCC) is one of the most frequent primary sites for metastatic pancreatic tumors although metastatic tumors are rare among pancreatic malignant tumors. The purpose of this study is to disclose the characterization and treatment outcomes of pancreatic metastases from RCC. METHODS: Of 262 patients with metastatic RCC treated at our hospital between 1999 and 2013, the data of 20 (7.6%) who simultaneously developed or subsequently acquired pancreatic metastases were retrospectively reviewed and statistically analyzed. RESULTS: The median follow-up period from RCC diagnosis and pancreatic metastases was 13.4 years (inter-quartile range: IQR, 7.8–15.5 years) and 3.8 years (IQR, 2.1–5.5 years), respectively. Median duration from diagnosis of RCC to pancreatic metastasis was 7.8 years (IQR, 4.2–12.7 years). During this observation period, the estimated median overall survival (OS) time from the diagnosis of RCC to death or from pancreatic metastasis to death was not reached. The probability of patients surviving after pancreatic metastasis at 1, 3, and 5 years was 100, 87.7, and 78.9%, respectively. The estimated OS period from the diagnosis of metastases to death of the patients with pancreatic metastasis was significantly longer than that of the patients with non-pancreatic metastasis (median OS 2.7 years) (P < 0.0001). Surgical management for pancreatic metastasis was performed in 15 patients (75%). When the median follow-up period for these surgeries was 3.5 years (IQR, 1.9–5.2 years), the estimated median recurrence-free survival was 1.8 years. For the patients with multiple metastatic sites, molecularly targeted therapies were given to six (30%) patients. When the median follow-up period was 4.1 years (IQR, 3.0–4.4 years), no disease progression was observed. CONCLUSIONS: The pancreas is frequently the only metastatic site and metastasis typically occurs a long time after nephrectomy. The OS period of these patients is long and both surgical and medical treatment resulted in good outcomes. BioMed Central 2015-02-12 /pmc/articles/PMC4332740/ /pubmed/25872621 http://dx.doi.org/10.1186/s12885-015-1050-2 Text en © Yuasa et al.; licensee BioMed Central. 2015 This article is published under license to BioMed Central Ltd. This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly credited. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.
spellingShingle Research Article
Yuasa, Takeshi
Inoshita, Naoko
Saiura, Akio
Yamamoto, Shinya
Urakami, Shinji
Masuda, Hitoshi
Fujii, Yasuhisa
Fukui, Iwao
Ishikawa, Yuichi
Yonese, Junji
Clinical outcome of patients with pancreatic metastases from renal cell cancer
title Clinical outcome of patients with pancreatic metastases from renal cell cancer
title_full Clinical outcome of patients with pancreatic metastases from renal cell cancer
title_fullStr Clinical outcome of patients with pancreatic metastases from renal cell cancer
title_full_unstemmed Clinical outcome of patients with pancreatic metastases from renal cell cancer
title_short Clinical outcome of patients with pancreatic metastases from renal cell cancer
title_sort clinical outcome of patients with pancreatic metastases from renal cell cancer
topic Research Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4332740/
https://www.ncbi.nlm.nih.gov/pubmed/25872621
http://dx.doi.org/10.1186/s12885-015-1050-2
work_keys_str_mv AT yuasatakeshi clinicaloutcomeofpatientswithpancreaticmetastasesfromrenalcellcancer
AT inoshitanaoko clinicaloutcomeofpatientswithpancreaticmetastasesfromrenalcellcancer
AT saiuraakio clinicaloutcomeofpatientswithpancreaticmetastasesfromrenalcellcancer
AT yamamotoshinya clinicaloutcomeofpatientswithpancreaticmetastasesfromrenalcellcancer
AT urakamishinji clinicaloutcomeofpatientswithpancreaticmetastasesfromrenalcellcancer
AT masudahitoshi clinicaloutcomeofpatientswithpancreaticmetastasesfromrenalcellcancer
AT fujiiyasuhisa clinicaloutcomeofpatientswithpancreaticmetastasesfromrenalcellcancer
AT fukuiiwao clinicaloutcomeofpatientswithpancreaticmetastasesfromrenalcellcancer
AT ishikawayuichi clinicaloutcomeofpatientswithpancreaticmetastasesfromrenalcellcancer
AT yonesejunji clinicaloutcomeofpatientswithpancreaticmetastasesfromrenalcellcancer